Last updated on May 2017

Dose Escalation Study of QR-010 in Homozygous F508 Cystic Fibrosis Patients

Brief description of study

A randomized, double-blind, placebo-controlled study of single and multiple ascending doses of QR-010 in adults homozygous for ΔF508 Cystic Fibrosis.

Detailed Study Description

The purpose of this study is to evaluate the safety, tolerability, and to determine the pharmacokinetics of QR-010 administered via inhalation in adult homozygous for ΔF508 Cystic Fibrosis.

Clinical Study Identifier: NCT02532764

Contact Investigators or Research Sites near you

Start Over

Adupa Rao, MD

University of Southern California USC - Keck School of Medicine
Los Angeles, CA United States
  Connect »

Richard Moss, MD

Stanford University
Palo Alto, CA United States
  Connect »

Manu Jain, MD

Northwestern University
Chicago, IL United States
  Connect »

Joel Mermis, MD

University of Kansas Medical Center Research Institute
Kansas City, KS United States
  Connect »

Isabel Neuringer, MD

Massachusetts General Hospital
Boston, MA United States
  Connect »

Alicia Casey, MD

Boston Children's Hospital
Boston, MA United States
  Connect »

Daniel Rosenbluth, MD

Washington University School of Medicine
Saint Louis, MO United States
  Connect »

Karen McCoy, MD

Nationwide Children's Hospital
Columbus, OH United States
  Connect »

Robert Vender, MD

Penn State Milton S. Hershey Medical Center
Hershey, PA United States
  Connect »

Patrick Flume, MD

Medical University of South Carolina
Charleston, SC United States
  Connect »

Raksha Jain, MD

University of Texas Southwestern Medical Center
Dallas, TX United States
  Connect »

Moira Aitken, MD

University of Washington Medical Center
Seattle, WA United States
  Connect »

Anne Malfroot, Professor

Universitair Ziekenhuis Brussel
Brussels, Belgium
  Connect »

Christiane De Boeck, MD

University of Leuven
Leuven, Belgium
  Connect »

Michael Parkins, MD

University of Calgary (Health Sciences Centre)
Calgary, AB Canada
  Connect »